228 related articles for article (PubMed ID: 18932097)
41. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.
Liotta M; Rose PG; Escobar PF
Gynecol Oncol; 2009 Nov; 115(2):308-9. PubMed ID: 19740533
[No Abstract] [Full Text] [Related]
42. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
43. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
Bodoky G
Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
[TBL] [Abstract][Full Text] [Related]
44. Antiangiogenic treatment for multiple CNS hemangioblastomas.
Riklin C; Seystahl K; Hofer S; Happold C; Winterhalder R; Weller M
Onkologie; 2012; 35(7-8):443-5. PubMed ID: 22846977
[TBL] [Abstract][Full Text] [Related]
45. Bevacizumab for advanced breast cancer.
Traina TA; Rugo HS; Dickler M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
[TBL] [Abstract][Full Text] [Related]
46. Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors.
Wong H; Yau T; Man CW; Epstein RJ
Acta Oncol; 2009; 48(8):1213-5. PubMed ID: 19863234
[No Abstract] [Full Text] [Related]
47. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825.
Weller M; Yung WK
Neuro Oncol; 2013 Aug; 15(8):971. PubMed ID: 23864129
[No Abstract] [Full Text] [Related]
48. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
Reinacher-Schick A; Pohl M; Schmiegel W
Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
[TBL] [Abstract][Full Text] [Related]
49. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.
Grabner G; Nöbauer I; Elandt K; Kronnerwetter C; Woehrer A; Marosi C; Prayer D; Trattnig S; Preusser M
Magn Reson Imaging; 2012 Jan; 30(1):139-47. PubMed ID: 21982163
[TBL] [Abstract][Full Text] [Related]
50. Bevacizumab (Avastin).
Mukherji SK
AJNR Am J Neuroradiol; 2010 Feb; 31(2):235-6. PubMed ID: 20037132
[TBL] [Abstract][Full Text] [Related]
51. Antiangiogenic therapies for glioblastoma.
Arrillaga-Romany I; Norden AD
CNS Oncol; 2014; 3(5):349-58. PubMed ID: 25363007
[TBL] [Abstract][Full Text] [Related]
52. Bevacizumab in glioblastoma--still much to learn.
Fine HA
N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324
[No Abstract] [Full Text] [Related]
53. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Han ES; Monk BJ
Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
[No Abstract] [Full Text] [Related]
54. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
Onishi M; Kurozumi K; Ichikawa T; Date I
Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
[TBL] [Abstract][Full Text] [Related]
55. Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle.
Bocci G; Loupakis F
Pharmacogenomics; 2011 Aug; 12(8):1077-80. PubMed ID: 21843059
[No Abstract] [Full Text] [Related]
56. [Angiogenesis suppressing therapy applied to malignant glioma].
Takano S
Gan To Kagaku Ryoho; 2009 Jun; 36(6):941-7. PubMed ID: 19579331
[No Abstract] [Full Text] [Related]
57. Bevacizumab therapy for glioblastoma: a passionate discussion.
Desjardins A; Friedman HS
CNS Oncol; 2014 Jan; 3(1):1-3. PubMed ID: 25054891
[No Abstract] [Full Text] [Related]
58. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
[TBL] [Abstract][Full Text] [Related]
59. Antiangiogenic therapy of brain tumors: the role of bevacizumab.
Trevisan E; Bertero L; Bosa C; Magistrello M; Pellerino A; Rudà R; Soffietti R
Neurol Sci; 2014 Apr; 35(4):507-14. PubMed ID: 24442487
[TBL] [Abstract][Full Text] [Related]
60. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
